Distinct Recognition Modes of FXXLF and LXXLL Motifs by the Androgen Receptor
Open accessThe DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.
Abstract
Among nuclear receptors, the androgen receptor (AR) is unique in that its ligand-binding domain (LBD) interacts with the FXXLF motif in the N-terminal domain, resembling coactivator LXXLL motifs. We compared AR- and estrogen receptor alpha-LBD interactions of the wild-type AR FXXLF motif and coactivator transcriptional intermediary factor 2 LXXLL motifs and variants of these motifs. Random mutagenesis revealed a key role for the F residues in FXXLF motifs in high-affinity and selective AR LBD interaction. The FXXLF motif in full-length AR and transcriptional intermediary factor 2 LXXLL motifs competed for an overlapping binding site. A computer model of the AR LBD/AR FXXLF complex showed that the bulky F residues are buried in a deep coactivator-binding groove. The corresponding groove in estrogen receptor alpha LBD is considerably shallower, explaining lack of binding of any of the FXXLF motifs tested. FXXLF and LXXLL motif interaction depended on different charged amino acid residues in the AR LBD present at opposite ends of the coactivator groove. In conclusion, our data demonstrate the importance of a deep hydrophobic groove and alternative usage of charged amino acids in specifying peptide binding to the AR LBD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Instead, it preferentially binds to a FXXLF motif existing in the AR NTD (Dubbink et al., 2006; Dubbink et al., 2004; He et al., 2004).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Dubbink et al., 2004
Citations
Cites
CHARMM: A program for macromolecular energy, minimization, and dynamics calculations
Brooks, B. R., Bruccoleri, R. E., Olafson, B. D., States, D. J., Swaminathan, S., & Karplus, M. (1983) · Journal of Computational Chemistry · doi:10.1002/jcc.540040211 · Cited by 14,944
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
A signature motif in transcriptional co-activators mediates binding to nuclear receptors
Heery, D. M., Kalkhoven, E., Hoare, S., & Parker, M. G. (1997) · Nature · doi:10.1038/42750 · Cited by 2,128
Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ
Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., Kurokawa, R., Rosenfeld, M. G., Willson, T. M., Glass, C. K., & Milburn, M. V. (1998) · Nature · doi:10.1038/25931 · Cited by 1,958
Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators
McKenna, N. J., & O'Malley, B. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00641-4 · Cited by 1,463
Androgen Receptor Defects: Historical, Clinical, and Molecular Perspectives*
QUIGLEY, C. A., BELLIS, A. D., MARSCHKE, K. B., EL-AWADY, M. K., WILSON, E. M., & FRENCH, F. S. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-271 · Cited by 1,447
Androgen Receptor (AR) Coregulators: An Overview
Heinlein, C. A., & Chang, C. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0460 · Cited by 943
Structure and specificity of nuclear receptor–coactivator interactions
Darimont, B. D., Wagner, R. L., Apriletti, J. W., Stallcup, M. R., Kushner, P. J., Baxter, J. D., Fletterick, R. J., & Yamamoto, K. R. (1998) · Genes & Development · doi:10.1101/gad.12.21.3343 · Cited by 924
Bledsoe, R. K., Montana, V. G., Stanley, T. B., Delves, C. J., Apolito, C. J., McKee, D. D., Consler, T. G., Parks, D. J., Stewart, E. L., Willson, T. M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00817-6 · Cited by 818
Cited by
Sonneveld, E. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfi005 · Cited by 351
“Possibly, a more complex mechanism of activation with interaction between C- and N-terminus and interactions with specific coactivators (Dubbink et al., 2004; He et al., 2002) may be involved in the difficulty of AR-binding pollutants leading to activation of this receptor.”
BackgroundDiverse roles of androgen receptor (AR) domains in AR-mediated signaling
Claessens, F., Denayer, S., Van Tilborgh, N., Kerkhofs, S., Helsen, C., & Haelens, A. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06008 · Cited by 231
“…in more detail, the AR-AF-2 cleft differs from that of other nuclear receptors in that it is able to www.nursa.org NRS | 2008 | Vol. 6 | DOI: 10.1621/nrs.06008 | Page 6 of 13 accommodate aromatic side chains, like those of the 23FQNLF27-motif in the AR-NTD [Dubbink et al., 2004; Hur et al., 2004].”
InfluentialLavery, D. N., & Mcewan, I. J. (2005) · Biochemical Journal · doi:10.1042/bj20050872 · Cited by 227
Complex disease, gender and epigenetics
Kaminsky, Z., Wang, S., & Petronis, A. (2006) · Annals of Medicine · doi:10.1080/07853890600989211 · Cited by 209
“In a similar way, differences in AR and ER interactions with coactivator LXXLL motifs (88) may result in the recruitment of different epigenetic modifying coregulatory complexes between the sexes.”
BackgroundThe role of androgen receptor mutations in prostate cancer progression.
Brooke, G., & Bevan, C. (2009) · Current Genomics · doi:10.2174/138920209787581307 · Cited by 181
“Study of the crystal structure of the AR AF-2 surface has demonstrated the coactivator groove to be much deeper than that found in the other steroid receptors [47, 48].”
BackgroundCompartmentalization of androgen receptor protein–protein interactions in living cells
van Royen, M. E., Cunha, S. M., Brink, M. C., Mattern, K. A., Nigg, A. L., Dubbink, H. J., Verschure, P. J., Trapman, J., & Houtsmuller, A. B. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200609178 · Cited by 170
“The AR differs from the other SRs in that its LBD preferentially interacts with cofactors containing FxxLF rather than LxxLL motifs (Dubbink et al., 2004; Hur et al., 2004).”
BackgroundInfluentialSelf-citationNedelsky, N. B., Pennuto, M., Smith, R. B., Palazzolo, I., Moore, J., Nie, Z., Neale, G., & Taylor, J. P. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.034 · Cited by 166
Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes
Yu, X., Yi, P., Hamilton, R. A., Shen, H., Chen, M., Foulds, C. E., Mancini, M. A., Ludtke, S. J., Wang, Z., & O’Malley, B. W. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.06.031 · Cited by 154
Structural basis for nuclear hormone receptor DNA binding
Helsen, C., Kerkhofs, S., Clinckemalie, L., Spans, L., Laurent, M. R., Boonen, S., Vanderschueren, D., & Claessens, F. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.025 · Cited by 180
Centenera, M. M., Harris, J. M., Tilley, W. D., & Butler, L. M. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0017 · Cited by 145
Stepwise androgen receptor dimerization
van Royen, M. E., van Cappellen, W. A., de Vos, C., Houtsmuller, A. B., & Trapman, J. (2012) · Journal of Cell Science · doi:10.1242/jcs.096792 · Cited by 143
Self-citationDeterminants of Receptor- and Tissue-Specific Actions in Androgen Signaling
Pihlajamaa, P., Sahu, B., & Jänne, O. A. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1034 · Cited by 141
Allosteric Modulators of Steroid Hormone Receptors: Structural Dynamics and Gene Regulation
Kumar, R., & McEwan, I. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1033 · Cited by 135
Androgen receptor coregulators: recruitment via the coactivator binding groove
van de Wijngaart, D. J., Dubbink, H. J., van Royen, M. E., Trapman, J., & Jenster, G. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.007 · Cited by 122
Self-citationThe hinge region in androgen receptor control
Clinckemalie, L., Vanderschueren, D., Boonen, S., & Claessens, F. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.02.019 · Cited by 104
Duff, J., & McEwan, I. J. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0231 · Cited by 92
The Deubiquitinating Enzyme USP26 Is a Regulator of Androgen Receptor Signaling
Dirac, A. M. G., & Bernards, R. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0424 · Cited by 102
“AR has been shown to display increased affinity for FXXLF and FXXFF over LXXLL motifs (39, 40).”
BackgroundProhibitin, a protein downregulated by androgens, represses androgen receptor activity
Gamble, S. C., Chotai, D., Odontiadis, M., Dart, D. A., Brooke, G. N., Powell, S. M., Reebye, V., Varela‐Carver, A., Kawano, Y., Waxman, J., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209967 · Cited by 103
“contains an FxxIL motif that is similar to motifs recently shown to have high affinity for the AR (Dubbink et al., 2004; Hur et al., 2004).”
BackgroundIntrinsic disorder in the androgen receptor: identification, characterisation and drugability
McEwan, I. J. (2011) · Molecular BioSystems · doi:10.1039/c1mb05249g · Cited by 86
Mayeur, G. L., Kung, W.-J., Martinez, A. D., Izumiya, C., Chen, D. J., & Kung, H.-J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413336200 · Cited by 86
Brooke, G. N., Parker, M. G., & Bevan, C. L. (2008) · Oncogene · doi:10.1038/sj.onc.1210955 · Cited by 79
“However, the AR is idiosyncratic in that it appears to interact preferentially with phenylalanine-rich motifs, found in several AR coactivators including ARA70, FHL2 and gelsolin (Hsu et al., 2003; Dubbink et al., 2004; Hur et al., 2004; van de Wijngaart et al., 2006).”
BackgroundKim, S. B., Otani, Y., Umezawa, Y., & Tao, H. (2007) · Analytical Chemistry · doi:10.1021/ac0621571 · Cited by 68
Recent developments in antiandrogens and selective androgen receptor modulators
Haendler, B., & Cleve, A. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.002 · Cited by 80
van de Wijngaart, D. J., van Royen, M. E., Hersmus, R., Pike, A. C. W., Houtsmuller, A. B., Jenster, G., Trapman, J., & Dubbink, H. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602567200 · Cited by 66
Self-citationBeyond the Ligand-Binding Pocket: Targeting Alternate Sites in Nuclear Receptors
Caboni, L., & Lloyd, D. G. (2012) · Medicinal Research Reviews · doi:10.1002/med.21275 · Cited by 67
Hay, C. W., & McEwan, I. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032514 · Cited by 76
“Mutations K720E and R726L, which is implicated in a 6-fold increased risk of prostate cancer [64], reside in a positive cluster in helix 3 with lysine 720 creating a charged clamp with glutamate 897, and both residues participate in the binding of the FxxLF motif present in the AR-NTD as well as the LxxLL found in the…”
Backgroundvan de Wijngaart, D. J., Molier, M., Lusher, S. J., Hersmus, R., Jenster, G., Trapman, J., & Dubbink, H. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.039958 · Cited by 65
Self-citationEvidence for DNA-Binding Domain–Ligand-Binding Domain Communications in the Androgen Receptor
Helsen, C., Dubois, V., Verfaillie, A., Young, J., Trekels, M., Vancraenenbroeck, R., De Maeyer, M., & Claessens, F. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00151-12 · Cited by 63
“Regarding the AR, dimerization occurs primarily at the level of the DBD via the so-called D-box residues in the second zinc finger (51) as well as between the amino-terminal domain (NTD) and the LBD (21, 30).”
Bai, S., & Wilson, E. M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01672-07 · Cited by 63
“However, these same AF2 site mutations that disrupt AR FXXLF motif binding also inhibit AR AF2 recruitment of SRC/p160 coactivator LXXLL motifs, which bind with at least 5- to 10-fold-lower affinity than the FXXLF motifs present in AR (22, 23), putative AR coregulators (27, 32, 58), and peptides identified in peptide…”
BackgroundMolecular basis of androgen insensitivity syndromes
Hornig, N., & Holterhus, P. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111146 · Cited by 70
46,XY disorders of sex development – the undermasculinised male with disorders of androgen action
Werner, R., Grötsch, H., & Hiort, O. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.11.002 · Cited by 65
Hsu, C.-L., Liu, J.-S., Wu, P.-L., Guan, H., Chen, Y., Lin, A.-C., Ting, H., Pang, S., Yeh, S.-D., Ma, W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.009 · Cited by 58
Butini, S., Campiani, G., Borriello, M., Gemma, S., Panico, A., Persico, M., Catalanotti, B., Ros, S., Brindisi, M., Agnusdei, M., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701253t · Cited by 64
Neurotoxic effects of androgens in spinal and bulbar muscular atrophy
Parodi, S., & Pennuto, M. (2011) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2011.06.003 · Cited by 63
Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif
Jehle, K., Cato, L., Neeb, A., Muhle-Goll, C., Jung, N., Smith, E. W., Buzon, V., Carbó, L. R., Estébanez-Perpiñá, E., Schmitz, K., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.534859 · Cited by 53
“10 with the LBD with IC50 values of 4 and 10 μM for Bag-1L(1-20) and Bag-1L(61-80), respectively (Fig.”
BackgroundMethodInfluentialEighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
Estébanez‐Perpiñá, E., Bevan, C. L., & McEwan, I. J. (2021) · Cancers · doi:10.3390/cancers13030509 · Cited by 57
“There is also considerable evidence showing that maximal activity of the AR requires an intramolecular interaction between the NTD and the ligand-binding domain, termed the N/C interaction, that occurs when ligands bind [14,48].”
Backgroundvan de Wijngaart, D. J., Dubbink, H. J., Molier, M., de Vos, C., Trapman, J., & Jenster, G. W. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0280 · Cited by 55
“Previous screenings for novel AR-interacting motifs already demonstrated that W (Trp) residues could be compatible with binding to the AR coactivator binding groove when present at positions 1 and 5 (21, 25, 43).”
MethodInfluentialSelf-citationRetinoic acid receptor structures: the journey from single domains to full-length complex
Rastinejad, F. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-22-0113 · Cited by 54
Regulation of Androgen-Responsive Transcription by the Chromatin Remodeling Factor CHD8
Menon, T., Yates, J. A., & Bochar, D. A. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0421 · Cited by 49
Dubbink, H. J., Hersmus, R., Pike, A. C. W., Molier, M., Brinkmann, A. O., Jenster, G., & Trapman, J. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0348 · Cited by 47
Self-citationAurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer
Jones, D. L., Noble, M. E. M., Wedge, S. R., Robson, C. N., & Gaughan, L. (2017) · Scientific Reports · doi:10.1038/srep40957 · Cited by 55
“The N-terminal domain (NTD) of the AR is highly unstructured creating a multitude of binding surfaces for important protein interactions 24 .”
InfluentialAndrogen Physiology: Receptor and Metabolic Disorders
McEwan, I. J., & Brinkmann, A. O. (2016) · Cited by 46
Self-citationChhipa, R. R., Lee, K.-S., Oñate, S. A., Wu, Y., & Ip, C. C. Y. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0546 · Cited by 44
Multiple Binding Modes between HNF4α and the LXXLL Motifs of PGC-1α Lead to Full Activation
Rha, G. B., Wu, G., Shoelson, S. E., & Chi, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.052506 · Cited by 46
Androgen Receptor Gene Rearrangements: New Perspectives on Prostate Cancer Progression
Brand, L. J., & Dehm, S. M. (2013) · Current Drug Targets · doi:10.2174/1389450111314040005 · Cited by 44
“AF-2 has been shown to exert transcriptional activity in the presence of bound agonist by binding to nuclear receptor (NR)-box motifs in coactivators, such as SRC-2 [19], and is also capable of mediating intramolecular interaction with FxxLF or WxxLF motifs in the AR NTD [21].”
BackgroundJin, F., Claessens, F., & Fondell, J. D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.304519 · Cited by 45
Structural features discriminate androgen receptor N/C terminal and coactivator interactions
Askew, E. B., Minges, J. T., Hnat, A. T., & Wilson, E. M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.03.026 · Cited by 40
“Superimposed surface representation of AR FXXLF and TIF2 LXXLL motif peptides bound to AF2 in the AR LBD-testosterone complex AR-20-30 FXXLF (orange) and TIF2-740-753 LXXLL (yellow/green) motif peptides contact the AF2 surface flanked by AF2 helix 12 surface residues Glu-897 (AF2 E897, red) and helix 3 Lys-720 (H3 K72…”
BackgroundInfluentialRoggero, C. M., Jin, L., Cao, S., Sonavane, R., Kopplin, N. G., Ta, H. Q., Ekoue, D. N., Witwer, M., Ma, S., Liu, H., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01585-5 · Cited by 40
Steroid receptor/coactivator binding inhibitors: An update
Skowron, K. J., Booker, K., Cheng, C., Creed, S. M., David, B. P., Lazzara, P. R., Lian, A., Siddiqui, Z., Speltz, T. E., & Moore, T. W. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110471 · Cited by 41
“performed computer modelling, cellbased studies, and mutation-based analysis to investigate the interaction of the AR ligand binding domain (LBD) with the AR FXXLF motif and the transcriptional intermediary factor 2 (TIF2) LXXLL motif (Dubbink et al., 2004).”
MethodA Bioluminescent Probe for Salivary Cortisol
Kim, S. B., Takenaka, Y., & Torimura, M. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200220k · Cited by 33
Chiappori, F., D’Ursi, P., Ivan Merelli, A., Milanesi, L., & Rovida, E. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-s12-s3 · Cited by 29
“Several examples are reported in literature that show how this approach has contributed to the clarification of ligand interaction in G protein coupled receptors [6,7], in nuclear receptors [8,9] and in EphA3/ ephrin-A5 [10], to cite a few examples.”
BackgroundBiron, É., & Bédard, F. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.07.006 · Cited by 28
Pippione, A. C., Boschi, D., Pors, K., Oliaro‐Bosso, S., & Lolli, M. L. (2017) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.44 · Cited by 35
FRAP and FRET Methods to Study Nuclear Receptors in Living Cells
van Royen, M. E., Dinant, C., Farla, P., Trapman, J., & Houtsmuller, A. B. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-575-0_5 · Cited by 29
Self-citationAndrogen Receptor Modulators: A Marriage of Chemistry and Biology
McEwan, I. J. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.69 · Cited by 25
Molecular Tension-Indexed Bioluminescent Probe for Determining Protein−Protein Interactions
Kim, S. B., Sato, M., & Tao, H. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900330w · Cited by 23
Nemo-like kinase is a novel regulator of spinal and bulbar muscular atrophy
Todd, T. W., Kokubu, H., Miranda, H. C., Cortes, C. J., La Spada, A. R., & Lim, J. (2015) · eLife · doi:10.7554/elife.08493 · Cited by 21
“K720A is a partial AF-2 mutation that neutralizes the charge of one of the clamps, preventing LxxLL motif binding and reducing FxxLF motif binding by 50% (Dubbink et al., 2004; Nedelsky et al., 2010).”
BackgroundBTG2 is an LXXLL-dependent co-repressor for androgen receptor transcriptional activity
Hu, X., Meng, Q., Xu, J., Jiao, Y., Ge, C., Jacob, A., Wang, P., Rosen, E. M., & Fan, S. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.064 · Cited by 19
“So far, a large number of co-factor proteins have been identified to be involved in the regulation of AR activity [3].”
BackgroundInfluentialBrooke, G. N., Gamble, S. C., Hough, M. A., Begum, S., Dart, D. A., Odontiadis, M., Powell, S. M., Fioretti, F. M., Bryan, R. A., Waxman, J. H., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.036764 · Cited by 20
“The AF-2 coactivator interaction groove consists of a hydrophobic cleft with charge-clamp residues (Lys720 and Glu897) situated at either end (14, 33).”
BackgroundUmar, A., Berrevoets, C., Van, N. M., van Leeuwen, M., Verbiest, M. M. P. J., Kleijer, W. J., Dooijes, D., Grootegoed, J. A., Drop, S. L. S., & Brinkmann, A. O. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0057 · Cited by 19
Self-citationWerner, R., Zhan, J., Gesing, J. K., Struve, D., & Hiort, O. (2008) · Sexual Development · doi:10.1159/000129692 · Cited by 15
“LXXLL motif containing cofactors like TIF2 and SRC1e are also able to enhance transcriptional activity from the isolated AR-LBD [Askew et al., 2007, Estebanez-Perpina et al., 2004], ( fig.”
BackgroundWong, H. Y., Hoogerbrugge, J. W., Pang, K. L., van Leeuwen, M., van Royen, M. E., Molier, M., Berrevoets, C., Dooijes, D., Dubbink, H. J., van de Wijngaart, D. J., et al. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.06.016 · Cited by 14
“…dissociation constant (Elhaji et al., 2004 prostate cancer, several mutations (V715M, R726L, H874Y) have been reported displaying either an increased NC-TDI or an increased p160 co-activator activation or both (Thompson et al., 2001; Duff and McEwan, 2005; He et al., 2006; Brooke et al., 2008).”
Self-citationAndrogen receptors in early and castration resistant prostate cancer: friend or foe?
Pelekanou, V., Notas, G., Stathopoulos, E. N., Castanas, E., & Kampa, M. (2013) · HORMONES · doi:10.14310/horm.2002.1406 · Cited by 15
“co-regulators, even though AF-2 has a low affinity.(4) Interestingly, the AF-2 of AR, in contrast to other nuclear receptors, primarily interacts with coactiva-”
BackgroundFolkertsma, S., van Noort, P. I., de Heer, A., Carati, P., Brandt, R., Visser, A., Vriend, G., & de Vlieg, J. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0072 · Cited by 15
DNA binding alters ARv7 dimer interactions
Özgün, F., Kaya, Z., Morova, T., Geverts, B., Abraham, T. E., Houtsmuller, A. B., van Royen, M. E., & Lack, N. A. (2021) · Journal of Cell Science · doi:10.1242/jcs.258332 · Cited by 12
Molecular signaling involving intrinsically disordered proteins in prostate cancer
Marasco, D., Russo, A., Manna, S. L., Novellino, E., & Malfitano, A. M. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.181817 · Cited by 13
The role of cofactors in sex steroid action
Trapman, J., & Dubbink, H. J. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.07.002 · Cited by 15
Self-citationvan de Wijngaart, D. J., Dubbink, H. J., Molier, M., de Vos, C., Jenster, G. W., & Trapman, J. (2011) · The Prostate · doi:10.1002/pros.21238 · Cited by 13
“1 QPKHFTELYFKS [39] D11 FxxLF ESGSSRFMQLFMANDL [50] D30 FxxLF PTHSSRFWELFMEATP [31] FLET 2 SSKFAALWDPPKLSR [26] FLET 5 SSNTPRFKEYFMQSR [26] FLET 6 RFADFFRNEGLSGSR [26] Gelsolin GGETPLFKQFFKNWRD [40] PAK6 SLKRRLFRSMFLSTAA [40] RAD9 TPPPKKFRSLFFGSIL [51] SRC1 box I SQTSHKFVQLFTTTAE [31] SRC1 box IV PQAQQKSLFQQLFTE [31]…”
BackgroundMethodSelf-citationGeorget, V., Bourguet, W., Lumbroso, S., Makni, S., Sultan, C., & Nicolas, J. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0419 · Cited by 12
Liang, J., Wang, D., Wu, Y., Shi, J., Xie, B., Xiao, R., Ni, J., Wang, C., Dong, C., Shu, H., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00425 · Cited by 12
Domínguez, M., Petkau‐Milroy, K., Vaz, B., Möcklinghoff, S., Folkertsma, S., Milroy, L. ‐., & Brunsveld, L. (2013) · MedChemComm · doi:10.1039/c2md20182h · Cited by 11
Engineered repressors are potent inhibitors of androgen receptor activity
Brooke, G. N., Powell, S. M., Lavery, D. N., Waxman, J. H., Buluwela, L., Ali, S., & Bevan, C. L. (2014) · Oncotarget · doi:10.18632/oncotarget.1360 · Cited by 11
“However, the AR differs from other steroid receptors in that it has greater affinity for phenylalanine rich motifs, such as the FQNLF motif found in the N-terminus of the AR that mediates the N-/Cterminal interaction, and those found in coactivators such as ARA70 [9] [10] [11].”
Mobisson, S. K., Ikpi, D. E., Wopara, I., Obembe, A. O., & Omotuyi, O. I. (2022) · Andrologia · doi:10.1111/and.14454 · Cited by 10
“AF-2 is responsible for activity in the presence of bound agonist through interactions with the N-terminal FXXFL motif intramolecularly or other coactivator proteins containing the LXXLL or FXXFL motifs (Dubbink et al., 2004).”
Backgroundvan Royen, M. E., van de Wijngaart, D. J., Cunha, S. M. P. R. M., Trapman, J., & Houtsmuller, A. B. (2013) · Cytometry Part A · doi:10.1002/cyto.a.22284 · Cited by 10
“It has been suggested that the AR N/C-interaction plays a role in the stability of ligand binding and also protects the cofactor groove for untimely and unfavorable protein–protein interactions (9,13,14).”
BackgroundSelf-citationKharraz, S. E., Dubois, V., Launonen, K., Helminen, L., Palvimo, J. J., Libert, C., Smeets, E., Moris, L., Eerlings, R., Vanderschueren, D., et al. (2022) · Endocrinology · doi:10.1210/endocr/bqac104 · Cited by 9
Elfferich, P., Juniarto, A. Z., Dubbink, H. J., van Royen, M. E., Molier, M., Hoogerbrugge, J. W., Houtsmuller, A. B., Trapman, J., Santosa, A., de Jong, F. H., et al. (2009) · Sexual Development · doi:10.1159/000252814 · Cited by 9
“The Gal4-DBD-AR FxxLF expression construct has been described previously [Dubbink et al., 2004].”
BackgroundMethodResultInfluentialSelf-citationZakharov, M. N., Pillai, B. K., Bhasin, S., Ulloor, J., Istomin, A. Y., Guo, C., Godzik, A., Kumar, P., & Jasuja, R. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.03.003 · Cited by 12
“Consensus peptide sequences, typically 15-30 amino acid long encompassing distinct motifs including but not limited to FxxLF and LxxLL, have proven to be useful tools in dissecting out the steps in the AR signaling cascade and in identifying binding partners (Zhou et al., 2002; Chang and McDonnell, 2002; He and Wilson…”
BackgroundKim, S. B., Umezawa, Y., & Tao, H. (2009) · Analytical Sciences · doi:10.2116/analsci.25.1415 · Cited by 9
Elfferich, P., van Royen, M. E., van de Wijngaart, D. J., Trapman, J., Drop, S. L. S., van den Akker, E. L. T., Lusher, S. J., Bosch, R., Bunch, T., Hughes, I. A., et al. (2013) · Sexual Development · doi:10.1159/000351820 · Cited by 10
“The Gal4-DBD-AR FxxLF, the Gal4-DBD-Gelsolin FxxFF and the Gal4-DBD-SRC -3box1 LxxLL peptide expression constructs have been described previously [Dubbink et al., 2004; Van de Wijngaart et al., 2006, 2012].”
BackgroundMethodSelf-citationFancher, A. T., Hua, Y., Strock, C. J., & Johnston, P. A. (2019) · Assay and Drug Development Technologies · doi:10.1089/adt.2019.940 · Cited by 8
“It has been reported that the LXXLL motif from box III of the TIF2 NID contributes most of the binding interactions with the AR AF-2 surface.(37,39,56,57) In our assay, the histidine-tagged AR-LBD protein was”
BackgroundNatural extranuclear androgen receptor ligands as endocrine disruptors of cancer cell growth
Kampa, M., Notas, G., & Castanas, E. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.021 · Cited by 7
Gender trend of monkeypox virus infection
Orassay, A., Diassova, A., Berdigaliyev, A., Liu, D., Makhmutova, Z., Amin, A., & Xie, Y. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2200163 · Cited by 7
Functional Motifs of the Androgen Receptor
Wilson, E. M. (2009) · Springer eBooks · doi:10.1007/978-0-387-69179-4_11 · Cited by 8
“association with FXXLF motif binding compared to the bound coactivator LXXLL motif (Dubbink et al. 2004; Hur et al. 2004).”
BackgroundEpigenetic Coregulation of Androgen Receptor Signaling
Fernandes, R. C., Leach, D. A., & Bevan, C. L. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_16 · Cited by 8
Bonagura, T. W., Deng, M., & Brown, T. R. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.08.012 · Cited by 8
The androgen receptor amino-terminal domain: structure, function and therapeutic potential
Hunter, I., Jamieson, C., & McEwan, I. J. (2025) · Endocrine Oncology · doi:10.1530/eo-24-0061 · Cited by 11
Androgen and estrogen receptors: Potential of crystallography in the fight against cancer
Nahoum, V., & Bourguet, W. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.01.001 · Cited by 6
Modi, P. K., Faiena, I., & Kim, I. Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800077-9.00003-7 · Cited by 8
Helsen, C., Nguyen, T. T., Vercruysse, T., Wouters, S. M. L., Daelemans, D., Voet, A. R. D., & Claessens, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031557 · Cited by 5
Habault, J., Schneider, J. A., Ha, S., Ruoff, R., Pereira, L. D., Puccini, J., Ranieri, M., Ayasun, R., Deng, J., Kasper, A. C., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0196 · Cited by 5
Mildenberger, E., Biesel, B., Siegel, G., & VERSMOLD, H. T. (2008) · Fetal Diagnosis and Therapy · doi:10.1159/000132410 · Cited by 7
Fancher, A. T., Hua, Y., Close, D. A., Xu, W., McDermott, L. A., Strock, C. J., Santiago, U., Camacho, C. J., & Johnston, P. A. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.08.001 · Cited by 4
“The LXXLL motifs of p160/SRC CoAs mediate binding to the AF-2 surface of AR resulting in activation of gene transcription [30,36–38].”
Androgen Receptor Gene Rearrangements: New Perspectives on Prostate Cancer Progression
Brand, L. J., & Dehm, S. M. (2013) · Current Drug Targets · doi:10.2174/13894501113149990151 · Cited by 4
Falconieri, A., Boarolo, G., Boschelle, C., Spagnolli, G., Marchioretti, C., Zuccaro, E., Palazzolo, I., Tosatto, L., Hegazy, A. K. O., Rosati, J. D., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf688 · Cited by 3
“AR is unique among nuclear receptors because it forms N / C interactions via the FxxLF motif [ 12 , 48 ], which trigger a conformational change in the AF-2 surface of the LBD [ 13 , 68 ].”
Androgens—Molecular Basis and Related Disorders
Meaden, C., & Chedrese, P. J. (2009) · Springer eBooks · doi:10.1007/978-0-387-88186-7_18 · Cited by 5
Androgen receptor and its coregulators in sex-biased diseases
Basso, M., Marchioretti, C., Zito, S., Zuccaro, E., & Pennuto, M. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.10.005 · Cited by 3
Lisberg, A. E., Liu, Y., & Merry, D. E. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107246 · Cited by 2
“This conformational change involves binding of the 23 FQNLF 27 domain in the N-terminus of AR to the AF2 domain within the AR C-terminal domain (17 – 19).”
Selective and Classical Androgen Response Elements in Androgen-Regulated Gene Expression
Claessens, F., Clinckemalie, L., Helsen, C., Spans, L., Dubois, V., Laurent, M. R., Boonen, S., & Vanderschueren, D. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6182-1_2 · Cited by 3
Twenty-five Years of Nuclear Receptor Structure Analysis: From the Laboratory to the Clinic
McEwan, I. J., & Kumar, P. (2015) · Springer eBooks · doi:10.1007/978-3-319-18729-7_1 · Cited by 2
Song, T.-Q., & Li, J. (2019) · Current Computer - Aided Drug Design · doi:10.2174/1573409915666190502153307 · Cited by 2
“As previously reported, +4 position of the groove is more suitable for accommodating bulky side chains [10].”
Metadata
- Authors
- Dubbink, H. J., Hersmus, R., Verma, C. S., van der Korput, H. A. G. M., Berrevoets, C. A., van Tol, J., Ziel-van der Made, A. C. J., Brinkmann, A. O., Pike, A. C. W., & Trapman, J.
- Affiliations
- Department of Pathology (H.J.D., R.H., H.A.G.M.v.d.K., J.v.T., A.C.J.Z.-v.d.M., J.T.), 3000 DR Rotterdam, The Netherlands
- University of York (GB)
- Erasmus MC (NL)
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2004-09-01
- Volume
- 18
- Issue
- 9
- Pages
- 2132-2150
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W1984435545
- Cited by
- 118
- References
- 63
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 2 · 2020: 3 · 2019: 3 · 2017: 3 · 2016: 3 · 2015: 7 · 2014: 3 · 2013: 8 · 2012: 9
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Molecular Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- androgen receptor, LXXLL motif, ligand-binding domain, coactivator binding, estrogen receptor alpha, peptide binding, hydrophobic groove, charged amino acids, nuclear receptor coactivators, random mutagenesis, binding site competition
- MeSH terms
- Amino Acid Sequence, Binding Sites, Binding, Competitive, DNA Mutational Analysis, Humans, Ligands, Models, Molecular, Molecular Sequence Data, Peptides, Protein Conformation, Receptors, Androgen, Transcription Factors, Amino Acid Substitution, Two-Hybrid System Techniques, Amino Acid Motifs, Estrogen Receptor alpha, Nuclear Receptor Coactivator 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.